Anti-CTLA4 treatment reduces lymphedema risk potentially through a systemic expansion of the FOXP3+ Treg population

Anti-CTLA4 treatment reduces lymphedema risk potentially through a systemic expansion of the FOXP3+ Treg population

Abstract Secondary lymphedema is a common sequel of oncologic surgery and presents a global health burden still lacking pharmacological treatment. The infiltration of the lymphedematous extremities with CD4+T cells influences lymphedema onset and emerges as a promising therapy target. Here, we show...

Full description

Saved in:
Bibliographic Details
Main Authors: Stefan Wolf, Matiar Madanchi, Patrick Turko, Maija Hollmén, Sonia Tugues, Julia von Atzigen, Pietro Giovanoli, Reinhard Dummer, Nicole Lindenblatt, Cornelia Halin, Michael Detmar, Mitchell Levesque, Epameinondas Gousopoulos
Format: Article
Language:English
Published: Nature Portfolio 2024-12-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-024-55002-6
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41467-024-55002-6

Similar Items